American Society of Clinical Oncology

Oncology & Cancer

CAR T-Cell therapy sends multiple myeloma into lasting remission

In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ? chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or ...

page 2 from 7